Literature DB >> 11444820

Dominant negative farnesyltransferase alpha-subunit inhibits insulin mitogenic effects.

C S Solomon1, M L Goalstone.   

Abstract

Farnesylation of p21Ras is required for translocation to the plasma membrane and subsequent activation by growth factors. Previously we demonstrated that insulin stimulates the phosphorylation of farnesyltransferase (FTase) and its activity, whereby the amount of farnesylated p21Ras anchored at the plasma membrane is increased. Herein we report that substitution of alanine for two serine residues (S60A)(S62A) of the alpha-subunit of FTase creates a dominant negative (DN) mutant. VSMC expressing the FTase alpha-subunit (S60A)(S62A) clone showed a 30% decreased basal FTase activity concurrent with a 15% decrease in the amount of farnesylated p21Ras compared to controls. Expression of alpha-subunit (S60A,S62A) blunted FTase phosphorylation and activity in the presence of hyperinsulinemia, and inhibited insulin-stimulated increases in farnesylated p21Ras. Insulin-stimulated VSMC expressing the FTase alpha-subunit (S60A,S62A) showed decreased (i) phosphorylation of FTase, (ii) FTase activity, (iii) amounts of farnesylated p21Ras, (iv) DNA synthesis, and (v) migration. Thus, down-regulation of FTase activity appears to mitigate the potentially detrimental mitogenic effects of hyperinsulinemia on VSMC. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444820     DOI: 10.1006/bbrc.2001.5142

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Regulation of ERK5 by insulin and angiotensin-II in vascular smooth muscle cells.

Authors:  Girish Sharma; Marc Lee Goalstone
Journal:  Biochem Biophys Res Commun       Date:  2007-01-26       Impact factor: 3.575

2.  Transcriptional response of a common permissive cell type to infection by two diverse alphaherpesviruses.

Authors:  Neelanjana Ray; L W Enquist
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  The insulin receptor: a new target for cancer therapy.

Authors:  Roberta Malaguarnera; Antonino Belfiore
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-06       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.